ID

22715

Beschreibung

Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01578902

Link

https://clinicaltrials.gov/show/NCT01578902

Stichworte

Versionen (1)
  1. 10.06.17 10.06.17 -
Hochgeladen am

10. Juni 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT01578902

Englisch

Eligibility Prostate Cancer NCT01578902

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent signed (appendix a)
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
adult men greater than 18 years of age
Beschreibung

Gender | Adult | Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001675
UMLS CUI [3]
C0001779
histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally reviewed).
Beschreibung

Adenocarcinoma of prostate

Datentyp

boolean

Alias
UMLS CUI [1]
C0007112
clinical stage t1-t2b, gleason score < 6, and psa < 10 ng/ml
Beschreibung

TNM clinical staging | Gleason score | Prostate specific antigen measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2]
C3203027
UMLS CUI [3]
C0201544
less than 50% of biopsy cores +ve for cancer
Beschreibung

Biopsy Percentage Positive Malignant Neoplasms

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005558
UMLS CUI [1,2]
C0439165
UMLS CUI [1,3]
C1514241
UMLS CUI [1,4]
C0006826
less than 50% overall surface area involved with cancer
Beschreibung

Body Surface Area Percentage Involvement with Malignant Neoplasms

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0005902
UMLS CUI [1,2]
C0439165
UMLS CUI [1,3]
C1314939
UMLS CUI [1,4]
C0006826
neoadjuvant hormone suppression therapy is allowed. however, psa, must have been performed within 2 months of starting androgen suppression therapy. if androgen suppression therapy has been started lhrh agonist must be continued for a minimum of 3 months before initiation of gold fiducial marker insertion & radiotherapy planning.
Beschreibung

Hormone suppression therapy Neoadjuvant | Prostate specific antigen measurement | Androgen suppression | Luteinizing Hormone-releasing Hormone Agonist | Therapeutic radiology procedure Planned

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1535931
UMLS CUI [1,2]
C0600558
UMLS CUI [2]
C0201544
UMLS CUI [3]
C1515985
UMLS CUI [4]
C1518041
UMLS CUI [5,1]
C1522449
UMLS CUI [5,2]
C1301732
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior pelvic radiotherapy.
Beschreibung

Radiotherapy to pelvis

Datentyp

boolean

Alias
UMLS CUI [1]
C1536155
concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed insertion)
Beschreibung

Anticoagulants

Datentyp

boolean

Alias
UMLS CUI [1]
C0003280
diagnosis of bleeding diathesis
Beschreibung

Bleeding tendency

Datentyp

boolean

Alias
UMLS CUI [1]
C1458140
presence of a hip prosthesis
Beschreibung

Hip Prosthesis

Datentyp

boolean

Alias
UMLS CUI [1]
C0019560
pelvic girth >40cm (to ensure visibility of gold seeds on electronic portal imaging device)
Beschreibung

Pelvis Measurement of girth

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030797
UMLS CUI [1,2]
C0203911
large prostate (> 60 cm3) on imaging
Beschreibung

Large prostate Imaging

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0426732
UMLS CUI [1,2]
C0011923
severe lower urinary tract symptoms (international prostate symptom score > 15 or nocturia > 3)
Beschreibung

Lower Urinary Tract Symptoms Severe International prostate symptom score | Nocturia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0574785
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C1998280
UMLS CUI [2]
C0028734
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Prostate Cancer NCT01578902

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent signed (appendix a)
boolean
C0021430 (UMLS CUI [1])
Gender | Adult | Age
Item
adult men greater than 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001675 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
Adenocarcinoma of prostate
Item
histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally reviewed).
boolean
C0007112 (UMLS CUI [1])
TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
clinical stage t1-t2b, gleason score < 6, and psa < 10 ng/ml
boolean
C3258246 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0201544 (UMLS CUI [3])
Biopsy Percentage Positive Malignant Neoplasms
Item
less than 50% of biopsy cores +ve for cancer
boolean
C0005558 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,4])
Body Surface Area Percentage Involvement with Malignant Neoplasms
Item
less than 50% overall surface area involved with cancer
boolean
C0005902 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C1314939 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,4])
Hormone suppression therapy Neoadjuvant | Prostate specific antigen measurement | Androgen suppression | Luteinizing Hormone-releasing Hormone Agonist | Therapeutic radiology procedure Planned
Item
neoadjuvant hormone suppression therapy is allowed. however, psa, must have been performed within 2 months of starting androgen suppression therapy. if androgen suppression therapy has been started lhrh agonist must be continued for a minimum of 3 months before initiation of gold fiducial marker insertion & radiotherapy planning.
boolean
C1535931 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
C1515985 (UMLS CUI [3])
C1518041 (UMLS CUI [4])
C1522449 (UMLS CUI [5,1])
C1301732 (UMLS CUI [5,2])
Item Group
C0680251 (UMLS CUI)
Radiotherapy to pelvis
Item
prior pelvic radiotherapy.
boolean
C1536155 (UMLS CUI [1])
Anticoagulants
Item
concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed insertion)
boolean
C0003280 (UMLS CUI [1])
Bleeding tendency
Item
diagnosis of bleeding diathesis
boolean
C1458140 (UMLS CUI [1])
Hip Prosthesis
Item
presence of a hip prosthesis
boolean
C0019560 (UMLS CUI [1])
Pelvis Measurement of girth
Item
pelvic girth >40cm (to ensure visibility of gold seeds on electronic portal imaging device)
boolean
C0030797 (UMLS CUI [1,1])
C0203911 (UMLS CUI [1,2])
Large prostate Imaging
Item
large prostate (> 60 cm3) on imaging
boolean
C0426732 (UMLS CUI [1,1])
C0011923 (UMLS CUI [1,2])
Lower Urinary Tract Symptoms Severe International prostate symptom score | Nocturia
Item
severe lower urinary tract symptoms (international prostate symptom score > 15 or nocturia > 3)
boolean
C0574785 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1998280 (UMLS CUI [1,3])
C0028734 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video